STOCK TITAN

Millennium Group discloses 8.4% BioXcel Therapeutics (BTAI) ownership in 13G/A

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

BioXcel Therapeutics, Inc. has an updated ownership disclosure as several Millennium-affiliated entities and Israel A. Englander filed an amended Schedule 13G reporting significant holdings of the company’s common stock. Millennium Management LLC, Millennium Group Management LLC and Mr. Englander each report beneficial ownership of 1,835,192 shares, representing 8.4% of the common stock. Integrated Core Strategies (US) LLC reports beneficial ownership of 1,833,717 shares, also representing 8.4% of the class. The filers state the securities are not held for the purpose of changing or influencing control of BioXcel Therapeutics.

Positive

  • None.

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does the Schedule 13G/A filing disclose about BioXcel Therapeutics (BTAI)?

The filing discloses that Millennium-affiliated entities and Israel A. Englander beneficially own a significant stake in BioXcel Therapeutics common stock. They report holdings of roughly 8.4% of the outstanding shares and certify the investment is not for changing or influencing control of the company.

How many BioXcel Therapeutics (BTAI) shares are beneficially owned by the Millennium entities?

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 1,835,192 shares of BioXcel Therapeutics common stock. This position represents 8.4% of the company’s outstanding common stock, according to the Schedule 13G/A disclosure.

What is Integrated Core Strategies (US) LLC’s ownership in BioXcel Therapeutics (BTAI)?

Integrated Core Strategies (US) LLC reports beneficial ownership of 1,833,717 shares of BioXcel Therapeutics common stock. This stake represents 8.4% of the company’s common stock class, with shared voting and dispositive power over all of these reported shares.

Who are the reporting persons in this BioXcel Therapeutics (BTAI) Schedule 13G/A?

The reporting persons are Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. All Millennium entities are organized in Delaware, while Mr. Englander is a United States citizen, according to the ownership disclosure.

Do the Millennium entities seek to influence control of BioXcel Therapeutics (BTAI)?

The reporting persons certify that their BioXcel Therapeutics shares were not acquired and are not held for the purpose of changing or influencing control. They also state the holdings are not part of any transaction designed to affect control, aside from activities tied to certain nomination rules.

What key dates are associated with this BioXcel Therapeutics (BTAI) ownership filing?

The date of the event triggering the Schedule 13G/A filing is listed as December 31, 2025. The joint filing agreement and signatures, including those by Gil Raviv and Israel A. Englander, are dated February 6, 2026 in the ownership disclosure.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Integrated Core Strategies (US) LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:02/06/2026
Millennium Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:02/06/2026
Millennium Group Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:02/06/2026
Israel A. Englander
Signature:/s/ Israel A. Englander
Name/Title:Israel A. Englander
Date:02/06/2026

Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner
Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of February 6, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.